David Shaw’s Apexigen, Inc. Common Stock APGN Stock Holding History

David Shaw’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-173,965	Closed	-$1.77M	–	5676
2022 Q2	$1.77M	Hold	173,965	–	–	﹤0.01%	3176
2022 Q1	$1.75M	Buy	173,965 +5,114	+3%	+$51.3K	﹤0.01%	3428
2021 Q4	$1.69M	Buy	168,851 +106,317	+170%	+$1.06M	﹤0.01%	3509
2021 Q3	$622K	Buy	+62,534	New	+$618K	﹤0.01%	3949

Other funds holding APGN

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Yu Fan $108M AUM 137.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's APGN Position: Q3 2022 in Review

David Shaw sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 173,965 shares — an estimated $1.77M sold.

David Shaw first reported a position in APGN in Q3 2021 and held it in 4 quarters. The position peaked at $1.77M in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

David Shaw reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
David Shaw sold 173,965 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $1.77M.
David Shaw first reported a position in Apexigen, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
David Shaw's Apexigen, Inc. Common Stock position peaked at $1.77M in Q2 2022.
18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.